MPACT control and experimental arms

First Line Therapy for Metastatic Pancreatic Cancer

Jamie Jarboe, Muhammad Wasif Saif

Abstract


Metastatic pancreatic cancer remains a difficult disease to treat; however, there are more new drug combinations on the horizon each week. We will discuss the results of the MPACT trial presented at the 2013 ASCO Annual Meeting (Abstracts #4005, #4058, and #4059) and compare to the 2011 FOLFIRINOX data.


Keywords


130-nm albumin-bound paclitaxel; CA-19-9 Antigen; oxaliplatin; Pancreatic Neoplasms

Full Text:

HTML PDF

References


Cancer Facts and Figures 2013. American Cancer Society

Burris HA, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-13, 1997.

Conroy T, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-25, 2011.

Von Hoff DD, Ervin TJ, Arena FP, Chiorean EG, Infante JR, Moore MJ, et al. Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates. J Clin Oncol 31, 2013(Suppl): Abstract #4005.

Komar G, et al. Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin Cancer Res 2009; 15:5511-7.

5. Von Hoff D, et al. Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial. JCO 2011;29:4548-4554.

Frese K, et al. nab-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer. Cancer Discovery 2012; 261-269.

Chiorean EG, Von Hoff DD, Ervin TJ, Arena FP, Infante JR, Bathini VG, et al. CA 19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC). J Clin Oncol 31, 2013(Suppl): Abstract #4058.

Moore MJ, Von Hoff DD, Ervin TJArena FP, Chiorean EG, Infante JR, et al. Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC). J Clin Oncol 31, 2013(Suppl): Abstract #4059.




DOI: http://dx.doi.org/10.6092%2F1590-8577%2F1667

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.